Financial Summary
Five Year Financial Summary
| Profit & Loss | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Revenues | A$m | 83.0 | 67.0 | 48.5 | 33.9 | 32.5 |
| Expenses | A$m | 37.4 | 32.7 | 22.7 | 22.4 | 14.4 |
| Net Profit / (Loss) | A$m | 30.6 | 20.9 | 24.7 | 15.1 | 18.1 |
| Balance Sheet | 2023 | 2022 | 2021 | 2020 | 2019 | |
| Cash & Cash equivalents | A$m | 156.8 | 121.5 | 82.7 | 66.7 | 54.3 |
| Total Assets | A$m | 193.7 | 143.9 | 108.6 | 81.5 | 62.3 |
| Total Liabilities | A$m | 29.1 | 18.4 | 9.8 | 9.5 | 5.2 |
| Equity | A$m | 164.6 | 125.6 | 98.7 | 72.1 | 57.2 |
| Cash Flow | 2023 | 2022 | 2021 | 2020 | 2019 | |
| Cashflow (used in ) operating v> | A$m | 36.9 | 39.9 | 19.3 | 14.2 | 18.4 |
| Net increase in cash held | A$m | 33.6 | 37.9 | 16.9 | 11.8 | 17.2 |
| Key Variables | 2023 | 2022 | 2021 | 2020 | 2019 | |
| Basic Earnings per Share | Cents | 61.9 | 42.3 | 50.0 | 30.6 | 37.6 |
| Net Tangible Assets Backing | A$ per share | 3.3 | 2.5 | 1.9 | 1.4 | 1.2 |
| Return on Equity | % | 19 | 17 | 25 | 21 | 32 |
Capital raisings
CLINUVEL has raised over A$95.0 million since 2006 to fund its clinical programme for afamelanotide.
| Date | Amount Raised A$m |
Shares Issued millions |
Price* A$ |
|---|---|---|---|
| Sep 2006 Rights Issue and Placement | 35.2 | 9.10 | 3.85 |
| Apr 2007 Placements | 26.0 | 2.40 | 10.70 |
| Jun 2012 Placements | 6.0 | 3.40 | 1.75 |
| May 2013 Placements | 6.3 | 2.98 | 2.14 |
| Jun 2014 Placements | 7.2 | 4.17 | 1.67 |
| Mar 2016 Placements | 8.3 | 2.53 | 3.30 |
* Represented on post-consolidated basis after capital re-organisation November 2010 (10:1 Reverse Stock Split)